ClinicalTrials.gg

Program

MTX-531

A development code.

Its studies are mostly in Squamous Cell Carcinoma of Head and Neck, led by MEKanistic Therapeutics.

Furthest: phase 1, since Oct 7, 20261 company-led study, 1 open or runningNext primary completion: Dec 31, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
MEKanistic Therapeutics11 open or runningphase 1since Oct 7, 2026Oct 7, 2026Dec 31, 2028phase 1 · NCT07874880

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 7, 2026First study: phase 1 study in Squamous Cell Carcinoma of Head and NeckFirst studyNCT07874880 · 71 planned · United States

Ahead

  1. Dec 31, 2028Primary completion: phase 1 study in Squamous Cell Carcinoma of Head and NeckNCT07874880

TargetBeta

EGFR →read by rule
“First-in-Human, Phase 1, Open-label Study to Evaluate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of MTX-531, a Dual EGFR/PI3K Inhibitor, as Monotherapy in Adults With Advanced Solid Tumors”study text, by rule · the study

Other programs on EGFR

ProgramCompanyFurthest phaseStudies
izalontamab brengitecanSichuan Biokin Pharmaceuticalphase 355
pimurutamabFosun Pharmaphase 317
Anti-EGFR Antibody-drug Conjugate CPO301CSPC Pharmaceutical Groupphase 316
sunvozertinibruleDizal Pharmaceuticalsphase 312
becotatugCSPC Pharmaceutical Groupphase 311
andamertinibruleavistone-biotechnology-co-ltdphase 310
becotatug vedotinrulelepu-biopharma-co-ltdphase 310
sevabertinibruleBayerphase 38
HS-10504Hansoh Pharmaceutical Groupphase 37
petosemtamabruleGenmabphase 36
bafisontamabruleshanghai-epimab-biotherapeutics-co-ltdphase 35
zipalertinibruleOtsukaphase 34

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07874880Squamous Cell Carcinoma of Head and Neck · United States1Not yet recruitingDec 31, 202871

How it is read

Names in the registry

  • “MTX-531”, 1 entry

Codes read as this program: MTX531.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.